NEON THERAPEUTICS
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
NEON THERAPEUTICS
Industry:
Bioinformatics Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.neontherapeutics.com
Total Employee:
101+
Status:
Closed
Contact:
(617)337-4701
Email Addresses:
[email protected]
Total Funding:
161 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA JQuery CDN Amazon Virginia Region ReCAPTCHA V2 IIS 8
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - Neon Therapeutics
ArrowMark Partners
ArrowMark Partners investment in Series B - Neon Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Neon Therapeutics
Nextech Invest
Nextech Invest investment in Series B - Neon Therapeutics
Access Industries
Access Industries investment in Series B - Neon Therapeutics
Wellington Management
Wellington Management investment in Series B - Neon Therapeutics
Inbio Ventures
Inbio Ventures investment in Series B - Neon Therapeutics
Partner Fund Management
Partner Fund Management investment in Series B - Neon Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Neon Therapeutics
Partner Fund Management
Partner Fund Management investment in Series B - Neon Therapeutics
Official Site Inspections
http://www.neontherapeutics.com
Unable to get host informations!!!
More informations about "Neon Therapeutics"
Neon Therapeutics - Crunchbase Company Profile
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The …See details»
BioNTech US
BioNTech US originated as Neon Therapeutics, which was acquired by BioNTech SE in 2020 to combine neoantigen expertise in the field of cancer medicine and immunology by leveraging the highly complementary capabilities and …See details»
Neon Therapeutics - LinkedIn
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune...See details»
Neon Therapeutics Company Profile 2024: Valuation, …
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. …See details»
Neon Therapeutics - Craft
Apr 10, 2020 · Thinking about buying stock in BioNTech, Chesapeake Energy, Digital Realty, Neon Therapeutics, or Waitr? See insights on Neon Therapeutics including office locations, …See details»
BioNTech Acquires Neon Therapeutics to Bolster …
Jan 17, 2020 · Mainz, Germany-based BioNTech announced it was acquiring Cambridge, Massachusetts-based Neon Therapeutics in an all-stock deal valued at about $67 million. Neon’s focus is on neoantigen therapies that have the …See details»
BioNTech to acquire Neon to strengthen global leadership
Jan 16, 2020 · Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage …See details»
Neon Therapeutics Launches with $55 Million Series A to Develop ...
Oct 1, 2015 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Third Rock Ventures, LLC today announced the formation of Neon Therapeutics, an immuno-oncology company developing …See details»
BioNTech Completes Acquisition of Neon Therapeutics - Nasdaq
May 6, 2020 · --BioNTech announced today the closing of the Neon Therapeutics, Inc. acquisition through an all-stock transaction. --AMC BEGIN ABOUT--> About BioNTech Biopharmaceutical …See details»
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics
Jan 16, 2020 · Once subsumed, Neon will work as a subsidiary of BioNTech and help boost its internal work on immunotherapies against cancer and other diseases.See details»
BioNTech rescues cancer biotech Neon in bargain buyout
Jan 16, 2020 · BioNTech, a German developer of cancer immunotherapies, will buy Neon Therapeutics in an all-stock deal worth $67 million, rescuing the Cambridge, Mass.-based …See details»
Neon Therapeutics Enters License Agreement with Sanquin for …
Neon Therapeutics plans to utilize the rapid UV-exchange tetramer technology to assay immunological activity for its cancer vaccines and T cell therapies, which will use both fully …See details»
Neon Therapeutics Announces FDA Acceptance Of ... - BioSpace
Jul 29, 2016 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to …See details»
BioNTech to acquire Neon to strengthen global leadership
Jan 16, 2020 · Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage …See details»
Neon Therapeutics Expands Board of Directors With Leading
Dec 12, 2017 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the …See details»
Neon Therapeutics Announces New Strategic Focus on Novel T
Nov 20, 2019 · Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors. Corporate restructuring effected to focus …See details»
Neon Therapeutics CEO and Key Executive Team | Craft.co
Neon Therapeutics's key executives include Hugh ODowd and 12 others. Need Data? Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via …See details»
Neon Therapeutics’ Personal Neoantigen Vaccine Study
Jul 15, 2019 · NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical …See details»
Neon Therapeutics Launches with $55 Million Series A to Develop ...
Oct 1, 2015 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Third Rock Ventures, LLC today announced the formation of Neon Therapeutics, an immuno-oncology company developing …See details»
Neon Therapeutics Presents Updated Data from Ongoing Phase
Mar 31, 2019 · Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer …See details»